mynth
08/2025100%

Organox acquired by Terumo

UNITED KINGDOM Life Sciences / Medical Devices EV €1–10bn

Context

Lauxera Capital Partners has successfully finalized the divestment of its minority equity stake in UK-based OrganOx to Japanese medical giant Terumo, marking the first historical exit for the medtech-focused growth investor. Since its initial entry into OrganOx’s capital by leading a £25 million funding round in 2023, followed by co-leading a $142 million expansion round in February 2025 alongside HealthQuest, Lauxera has successfully driven a five-fold increase in OrganOx’s revenue base within a two-year holding period. This rapid scale-up has generated a highly lucrative return on investment of over 100% for the growth sponsor. Strategically, this high-profile realization is positioned to significantly accelerate the institutional fundraising momentum for Lauxera’s second flagship vehicle, which targets €400 million with a hard cap of €500 million.

In the past, Organox was acquired by Lauxera in 2023 as part of its expansion strategy.

Organox, which reported an EBITDA margin of [members only] in 2025, is valued in this transaction at an EV/EBITDA multiple of Above 20x.

-> Deep-dive in Healthcare & Pharma market trends

Target

OrganOx is a UK-based company founded in 2008, originating from the University of Oxford, which markets a groundbreaking device that can keep a liver graft functional outside the human body for up to 24 hours, significantly increasing the number of grafts eligible for transplantation. With innovative technology and a dedicated team, OrganOx has become a major player in the transplantation field, with a steadily growing revenue and established profitability, having generated a profit of £7.5 million in 2024. The company provides cutting-edge solutions to improve transplantation outcomes and meet the growing needs of patients. OrganOx is a success story in the medtech sector, with a history marked by strategic partnerships and targeted investments, such as the £25 million funding round led by Lauxera in 2023, and the $142 million funding round co-led by HealthQuest and Lauxera last February.

Ent. Value

€1–10bn

Equity Value

[members only]

Multiples

EV / Revenue

Above 6x

EV / EBITDA

Above 20x

EV / EBIT

[members only]

Historical Financials (EUR)

Year
Rev
EBITDA
EBIT
2025
€100–200M
€10–30M
[members only]
2024
€100–200M
€10–30M
[members only]

Other operations with Organox

Other operations with Organox
DateAcquirerTargetCountrySector
07/2023LAUXERAORGANOXUNITED KINGDOMMedical Devices

Similar deals in Life Sciences

Similar deals in Life Sciences
DateAcquirerTargetCountrySector
09/2025CREDIT MUTUEL EQUITY / EURAZEO / BPIFRANCE / BNP PARIBAS DEVELOPPEMENTPROTEORFRANCEImplants & Prosthetics
09/2025CAPVEST PARTNERSSTADAGERMANYGenerics / Labs
08/2025LGT CAPITAL PARTNERSNEMERAFRANCEMedical Consumables
08/2025WARBURG PINCUSSEBIAFRANCEDiagnostic Equipment
08/2025PAI PARTNERSINNOVAD GROUPBELGIUMAnimal Health
07/2025PATRICIA INDUSTRIESNOVA BIOMEDICALUNITED STATESDiagnostic Equipment
07/2025BC PARTNERSBIOGARANFRANCEPharma & Biotech
05/2025OTTOBOCKMATTON ORTHOMEDIBELGIUMImplants & Prosthetics
05/2025IK PARTNERSBIOBANKFRANCEImplants & Prosthetics
04/2025PATIENT SQUARE CAPITALPATTERSON COMPANIESUNITED STATESMedical Consumables

REFERENCES

Valuation range: EV €1–10bn

Revenue range: €100–200M

EBITDA range: €10–30M

EV/Revenue range: Above 6x

EV/EBITDA range: Above 20x

Note: This page provides detailed data on a private equity M&A transaction. Detailed and exact financial metrics for the acquisition of Organox by Terumo are reserved for mynth community members. Register for free to unlock full data.

Authors: This transaction was contributed by a verified mynth contributor and cross-checked against available transaction documents and official company communications.

Press release: view release

Target: organox

FAQ

What transaction does this page cover?

This page covers Terumo’s acquisition of 100% of Organox, a British company specialised in Medical Devices, in 2025. This followed an earlier holding cycle initiated in July 2023, when the company was acquired by Lauxera.

How was the acquisition of Organox by Terumo valued, and what multiples were paid?

mynth displays the transaction’s enterprise value within the €1–10bn band, its EV/EBITDA multiple within the Above 20x range, and its EV/revenue multiple within the Above 6x range. Exact figures are available to members.

What were Organox’s revenue and EBITDA at the time of the deal?

At the time of the transaction, Organox generated annual revenue estimated in the €100–200M range and EBITDA in the €10–30M bracket (FY 2025). Detailed financial figures are available to members.

What sources support the information on this transaction?

Information on this transaction is sourced from the official corporate announcement published by the parties, corroborated by a private document shared by the community and verified by the mynth team to ensure the accuracy of the shared information.

What is mynth?

mynth is the first free M&A database dedicated to Small & Mid-Cap transactions. We centralize Enterprise Values, revenue multiples, EBITDA multiples and transaction financials that are typically locked behind five-figure subscriptions on platforms like Capital IQ or Mergermarket. On mynth, searching and browsing deals is completely free. Our mission is simple: make professional-grade valuation intelligence accessible to every M&A advisor, independent consultant, Private Equity professional and student, without the burden of expensive annual licenses.